ECP Histamin
(-)
KAYNAKLAR
4. Çelik G, Mungan D, Özer F, Ediger D, Bavbek S, Sin B, Demirel YS, Mısırlıgil Z. Clinical features and atopy profile in Turkish subjects with analgesic intolerance. J Asthma 2002;39:101-106.
5. Picado C, Castillo JA, Montserrat JM, August-Vidal A. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989;2:127-129.
6. Marguetto CH, Saulnier F, Leroy O, et al. Long term prognosis for near-fatal asthma.
Am Rev Respir Dis 1992;146:76-81.
7. Vane J. Aspirin and other anti-inflammatory drugs. Thorax 2000; 55(suppl 2):s3-s9.
8. Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol 1976;58:691-712.
9. Stevenson DD. Aspirin and nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 1995;15:529-549.
10.Picado C. Aspirin-intolerant asthma:role of cyclo-oxygenase enzymes.Allergy 2002;57 (suppl 72):58-60.
11.Szczeklik A. Mechanism of aspirin-induced asthma. Allergy 1997;52:613-619.
12.Lee TH. Mechanism of bronchospasm in aspirin-sensitive asthma. Am Rev Respir Dis 1993;148:1442-1443.
13.Kowalski ML. Aspirin-sensitive rhinosinusitis/asthma syndrome - pathophysiology and management. ACI International 1996;8:49-56.
14.Lee TH. Mechanism of aspirin sensitivity. Am Rev Respir Dis 1992;145(Suppl.):34-36.
15.Christie PE, Smith C, Arm JP, Lee TH. Aspirin-sensitive asthma. Clin Exp Allergy 1992;22:171-175.
16.Szczeklik A, Stevenson DD.Aspirin-induced asthma:advances in pathogenesis and management.J Allergy Clin Immunol 1999;104:5-13.
17.Peebles RS, Sheller JR. Role of prostaglandins in asthma. Immunol Allergy Clin North Am 2002;22:827-844.
18.Sestini P, Armetti L, Gambora G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;53:572-575.
19.Kumlin M. Measurement of leukotrienes in the urine: strategies and applications.
Allergy 1997;52:124-135.
20.Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992;119:48-51.
21.Kumlin M, Dahlen B, Bjork T, et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergens, aspirin, leukotriene D4 and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
22.Oosaki R, Mizushima Y, Mita H, et al. Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. Allergy 1997;52:470-473.
23.Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-399.
24.Smith CM, Hawskworth RJ, Thien FC, et al. Urinary leukotriene E4 in bronchial asthma.
Eur Respir J 1992;5:693-699.
25.Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-1614.
26.Picado C, Ramis I, Rosello J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir
27.Ferreri NR, Howland WC, Stevenson DD, Spielberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137:847-854.
28. Çelik G, Bavbek S, Mısırlıgil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leukocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001;31:1615-1622.
29.Expert Panel Report 2. Guidelines for the diagnosis and management of asthma.
National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland, USA. Publication no. 97-4051, July 1997.
30.Ulusal Astım Tanı ve Tedavi rehberi. Toraks Dergisi 2000 ; 1: ek 1.
31.Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996;26:868-879.
32.Sampson AP. The leukotrienes: Mediators of chronic inflammation in asthma. Clin Exp Allergy 1996;26:995-1004.
33.Kubota Y, Imayama S, Toshitani A, et al. Sulfidoleukotriene release test (CAST) in hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 1997;114:361-366.
34.Mewes T, Riechelmann H, Klimek L. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance.
Allergy 1996;51:506-510.
35.Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes P. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Repir Crit Care Med 2001;166:301-306.
36.Quaratino D, Romano A, Papa G, et al. Long-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patients. Ann Allergy Asthma Immunol 1997;9:47-50.
37.Bavbek S, Çelik G, Ediger D, et al. Use of Nimesulide in patients with aspirin intolerance. J Asthma 1999 36:657-663.
38.Bavbek S, Çelik G, Özer F, Mungan D, Mısırlıgil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drugs-intolerant patients: comparison of nimesulide, meloxicam and rofecoxib. J Asthma (Yayına kabul edildi).
39.Karakaya G, Kalyoncu AF. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergol Immunol Pathol (Madrid). 2000;28:319-321.
40.Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998;53:1231-1233.
41.Pavord ID, Wisnievski A, Mathur R, et al. Effect of inhaled prostoglandin E2 on bronchial reactivity to sodium metabisulfite and methacholine in patients with asthma.
Thorax 1991;46:633-637.
42.Pavord ID, Wong CS, Williams J, Tattersfield AE. Effect of inhaled PGE2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87-90.
43.Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996;26:807-814.
44.Nasser S, Christie PE, Pfister R, et al. Effect of endobrochial aspirin challange on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996;51:64-70.
45.Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90-96.
46.Juergens UR, Christansen SC, Stevenson DD, Zuraw BL. Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge. J Allergy Clin Immunol 1992;90:636-645.
47.Sampson AP, Cowburn AS, Sladek K, et al. Profound overexpression of leukotriene C4
synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol 1997;113:355-357.
48.In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-1137.
49.Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;29:599-600.
50.Dekker JW, Nizankowska E, Schmitz-Schumann M, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997;27:574-577.
51.Szczeklik A, Sanak M. Molecular mechanisms in aspirin-induced asthma.ACI International 2000;12:171-175.